Carregant...
Tipus de document
ArticleVersió
Versió publicadaData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/199469
Real-World Data on Chronic Myelomonocytic Leukemia: Clinical and Molecular Characteristics, Treatment, Emerging Drugs, and Patient Outcomes
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
Despite emerging molecular information on chronic myelomonocytic leukemia (CMML), patient outcome remains unsatisfactory and little is known about the transformation to acute myeloid leukemia (AML). In a single-center cohort of 219 CMML patients, we explored the potential correlation between clinical features, gene mutations, and treatment regimens with overall survival (OS) and clonal evolution into AML. The most commonly detected mutations were TET2, SRSF2, ASXL1, and RUNX1. Median OS was 34 months and varied according to age, cytogenetic risk, FAB, CPSS and CPSS-Mol categories, and number of gene mutations. Hypomethylating agents were administered to 37 patients, 18 of whom responded. Allogeneic stem cell transplantation (alloSCT) was performed in 22 patients. Two-year OS after alloSCT was 60.6%. Six patients received targeted therapy with IDH or FLT3 inhibitors, three of whom attained a long-lasting response. AML transformation occurred in 53 patients and the analysis of paired samples showed changes in gene mutation status. Our real-world data emphasize that the outcome of CMML patients is still unsatisfactory and alloSCT remains the only potentially curative treatment. However, targeted therapies show promise in patients with specific gene mutations. Complete molecular characterization can help to improve risk stratification, understand transformation, and personalize therapy.
Matèries
Matèries (anglès)
Citació
Citació
CASTAÑO DÍEZ, Sandra, LÓPEZ-GUERRA, Mónica, BOSCH CASTAÑEDA, Cristina, BATALLER, Alex, CHARRY, Paola, ESTEBAN, Daniel, GUIJARRO, Francesca, JIMÉNEZ VICENTE, Carlos, CASTILLO GIRÓN, Carlos, CORTES, Albert, MARTÍNEZ ROCA, Alexandra, TRIGUERO, Ana, ALAMO, José ramón, BEÀ BOBET, Sílvia m., COSTA, Dolors, COLOMER PUJOL, Dolors, ROZMAN, María, ESTEVE REYNER, Jordi, DÍAZ BEYÀ, Marina. Real-World Data on Chronic Myelomonocytic Leukemia: Clinical and Molecular Characteristics, Treatment, Emerging Drugs, and Patient Outcomes. _Cancers_. 2022. Vol. 14, núm. 17. [consulta: 14 de gener de 2026]. ISSN: 2072-6694. [Disponible a: https://hdl.handle.net/2445/199469]